fosravuconazole

Fosravuconazole is a triazole antifungal agent and a prodrug of ravuconazole, developed to improve hydrophilicity and oral bioavailability. It exerts its antifungal effect by inhibiting cytochrome P450 sterol 14α-demethylase, an enzyme critical for ergosterol biosynthesis in fungal cell membranes, leading to cell lysis and death. Fosravuconazole is approved in Japan under the brand name Nailin for the treatment of onychomycosis (fungal nail infection). It has also been investigated as a safe, effective, and affordable oral treatment for eumycetoma—a neglected tropical disease—especially where current therapies are limited or unaffordable. The drug was originally developed by Eisai and has been studied in collaboration with the Drugs for Neglected Diseases initiative (DNDi)[1][2][4][6].

Brand names

Nailin

Other names

ravuconazole phosphoesterfosravuconazole L‐lysine ethanolate